| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,620,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.1993 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Humanigen is a biopharmaceutical company focused on developing its immuno-oncology and immunology portfolio of monoclonal antibodies. Co. is focusing on the development of its key product candidate, lenzilumab, its Humaneered® anti-human GM-CSF immunotherapy, through a clinical research agreement to study the effect of lenzilumab on the safety of Yescarta®, axicabtagene ciloleucel including cytokine release syndrome, and neurotoxicity. Co. is creates combinatory gene-edited CAR-T therapies to improve efficacy. Co. is also developing its own chimeric antigen receptor T-cell programs based on the backbone of ifabotuzumab and HGEN005, in unmet medical need and rare/orphan oncology conditions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,042,996 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,263,990 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
386,350 |
386,350 |
| Total Sell Value |
$0 |
$0 |
$4,250 |
$4,250 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2021-06-18 |
4 |
S |
$18.50 |
$7,445,558 |
I/I |
(402,480) |
9,142,753 |
|
62% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2021-06-17 |
4 |
S |
$19.17 |
$3,478,441 |
I/I |
(181,423) |
9,434,551 |
|
65% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2021-06-16 |
4 |
S |
$19.40 |
$3,076,187 |
I/I |
(158,486) |
9,566,083 |
|
67% |
|
| Edward P. Jordan |
Chief Commercial Officer |
• – – |
2021-06-08 |
4 |
S |
$20.08 |
$295,176 |
D/D |
(14,700) |
0 |
|
68% |
|
| Edward P. Jordan |
Chief Commercial Officer |
• – – |
2021-06-08 |
4 |
OE |
$9.65 |
$141,855 |
D/D |
14,700 |
14,700 |
|
- |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2021-06-07 |
4 |
S |
$19.08 |
$1,538,793 |
I/I |
(80,636) |
9,677,408 |
|
69% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-06-04 |
4 |
S |
$18.46 |
$2,346,415 |
I/I |
(127,084) |
9,719,848 |
|
66% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-06-03 |
4 |
S |
$18.37 |
$3,511,308 |
I/I |
(191,154) |
9,786,734 |
|
66% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-06-02 |
4 |
S |
$19.01 |
$1,447,269 |
I/I |
(76,126) |
9,887,341 |
|
67% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-03-11 |
4 |
D |
$15.49 |
$587,257 |
D/D |
(37,912) |
5,342,887 |
|
- |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-03-11 |
4 |
S |
$16.02 |
$1,909,672 |
D/D |
(119,201) |
5,380,799 |
|
-10% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-03-10 |
4 |
S |
$16.46 |
$534,589 |
D/D |
(32,469) |
5,500,000 |
|
-4% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-03-09 |
4 |
S |
$17.24 |
$1,440,495 |
D/D |
(83,568) |
55,632,469 |
|
-2% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-03-01 |
4 |
S |
$18.65 |
$262,951 |
D/D |
(14,100) |
5,616,037 |
|
8% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-26 |
4 |
S |
$19.18 |
$575,437 |
D/D |
(30,003) |
5,630,137 |
|
10% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-25 |
4 |
S |
$19.17 |
$46,045 |
D/D |
(2,402) |
5,660,140 |
|
9% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-24 |
4 |
S |
$19.55 |
$506,333 |
D/D |
(25,906) |
5,662,542 |
|
15% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-22 |
4 |
S |
$23.21 |
$1,794,690 |
D/D |
(77,314) |
5,688,448 |
|
21% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-19 |
4 |
S |
$23.50 |
$876,364 |
D/D |
(37,300) |
5,765,762 |
|
27% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-18 |
4 |
S |
$21.70 |
$920,042 |
D/D |
(42,408) |
5,803,062 |
|
21% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-17 |
4 |
S |
$19.92 |
$193,214 |
D/D |
(9,700) |
5,845,470 |
|
13% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-13 |
4 |
S |
$19.68 |
$323,221 |
D/D |
(16,423) |
5,855,170 |
|
8% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-11 |
4 |
S |
$21.01 |
$11,555 |
D/D |
(550) |
5,871,593 |
|
13% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-10 |
4 |
S |
$21.39 |
$232,605 |
D/D |
(10,875) |
5,872,143 |
|
12% |
|
| Nomis Bay Ltd. |
10% Owner |
– – • |
2021-02-09 |
4 |
S |
$22.32 |
$572,942 |
D/D |
(25,666) |
5,883,018 |
|
12% |
|
160 Records found
|
|
Page 2 of 7 |
|
|
